The Neurology podcast is introduced by Editor-in-Chief Robert A. Gross, MD, PhD, who discusses several highlighted articles in the current issue of Neurology®. The podcast regularly features content from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation. Opening segments include interviews with authors who summarize a current article and discuss the main findings and clinical implications for neurologists. It concludes with the Lesson of the Week, a short segment on a topic such as a laboratory technique, statistical methods, or historical neurology. Regular features also include Delayed Recall, ePearls, and What’s Trending. Podcast listeners can earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions related to Neurology content in the online Podcast Quiz. (Delayed recall, Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation contents are excluded from the CME program). The exams are posted weekly on Wednesday.
https://www.neurology.org/podcast
Eine durchschnittliche Folge dieses Podcasts dauert 25m. Bisher sind 5408 Folge(n) erschienen.
Dieser Podcast erscheint alle 0 Tage
Drug pricing controversies (Delayed Recall October 2019)
Drug pricing controversies (Delayed Recall October 2019)
Combination therapy with nusinersen and AVXS-101 in SMA type 1
Combination therapy with nusinersen and AVXS-101 in SMA type 1
Gender Equity in Neurology + Drug Pricing Update Part 1
Gender Equity in Neurology + Drug Pricing Update Part 1
Checkpoint Inhibitior Associated Neuropathy + Next Gen Sequencing Diagnosis of Encephalitis
Checkpoint Inhibitior Associated Neuropathy + Next Gen Sequencing Diagnosis of Encephalitis
AAN Annual Meeting Plenary Session Speakers (Delayed Recall September 2019)
AAN Annual Meeting Plenary Session Speakers (Delayed Recall September 2019)
Nerve Agent Poisoning Update + Brain Activity in Acute Brain Injury
Nerve Agent Poisoning Update + Brain Activity in Acute Brain Injury
A new paraneoplastic biomarker + Drug pricing controversies: “Evergreening” in pharma
A new paraneoplastic biomarker + Drug pricing controversies: “Evergreening” in pharma